CLINICAL TRIALS PROFILE FOR PERMAX
✉ Email this page to a colleague
All Clinical Trials for PERMAX
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00260793 ↗ | Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease | Unknown status | Colorado Neurology | Phase 3 | 2005-11-01 | The purpose of this research study is to see if subjects with Parkinson's disease who are experiencing motor fluctuations ("on" and "off" states) and dyskinesias (involuntary excessive movements) would benefit from a higher dose of Requip as compared to the maximum FDA approved dose of dopamine agonist drugs (including Requip, Mirapex, and Permax). Requip as used in this study is investigational, which means it has not been approved by the US Food and Drug Administration (FDA) at this dose level. |
NCT00260793 ↗ | Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease | Unknown status | GlaxoSmithKline | Phase 3 | 2005-11-01 | The purpose of this research study is to see if subjects with Parkinson's disease who are experiencing motor fluctuations ("on" and "off" states) and dyskinesias (involuntary excessive movements) would benefit from a higher dose of Requip as compared to the maximum FDA approved dose of dopamine agonist drugs (including Requip, Mirapex, and Permax). Requip as used in this study is investigational, which means it has not been approved by the US Food and Drug Administration (FDA) at this dose level. |
NCT00260793 ↗ | Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease | Unknown status | Agarwal, Pinky, M.D. | Phase 3 | 2005-11-01 | The purpose of this research study is to see if subjects with Parkinson's disease who are experiencing motor fluctuations ("on" and "off" states) and dyskinesias (involuntary excessive movements) would benefit from a higher dose of Requip as compared to the maximum FDA approved dose of dopamine agonist drugs (including Requip, Mirapex, and Permax). Requip as used in this study is investigational, which means it has not been approved by the US Food and Drug Administration (FDA) at this dose level. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PERMAX
Condition Name
Clinical Trial Locations for PERMAX
Trials by Country
Clinical Trial Progress for PERMAX
Clinical Trial Phase
Clinical Trial Sponsors for PERMAX
Sponsor Name